Mouse retinoid X receptor contains a separable ligand-binding and transactivation domain in its E region - PubMed (original) (raw)

Comparative Study

Mouse retinoid X receptor contains a separable ligand-binding and transactivation domain in its E region

X Leng et al. Mol Cell Biol. 1995 Jan.

Abstract

Steroid, thyroid, and retinoid hormones exert their biological functions by interacting with their cognate nuclear receptors. Upon binding receptors, hormones induce a protease-resistant structural change in the receptor ligand-binding domain and subsequently activate the receptors. Utilizing partial proteolysis, we have been able to delineate a region in the mouse retinoid X receptor beta (mRXR beta) required for ligand binding. A separable activation domain within the mRXR beta E region has been identified. The activation domain, which is 21 amino acids in length, is located at the extreme C terminus of mRXR beta. This domain is not required for ligand binding since removal of this sequence neither eliminates the ligand-induced, protease-resistant conformational change nor alters the ligand-enhanced DNA binding. Furthermore, deletion of this activation domain converts the receptor into a transcriptional silencer. Finally, a further truncation of 9 amino acids (for a total of 30 amino acids) from the C terminus results in a mutant which does not undergo the protease-resistant conformational change and cannot bind DNA as a homodimer. Nevertheless, this mutant is still able to form a heterodimer with the thyroid hormone receptor. Therefore, homodimerization and heterodimerization can be distinguished by this nine-amino-acid sequence.

PubMed Disclaimer

References

    1. Semin Cancer Biol. 1990 Feb;1(1):81-7 - PubMed
    1. Cell. 1991 Dec 20;67(6):1251-66 - PubMed
    1. Nature. 1992 Jan 30;355(6359):441-6 - PubMed
    1. Nature. 1992 Jan 30;355(6359):446-9 - PubMed
    1. EMBO J. 1992 Mar;11(3):1015-23 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources